3D Medicines Inc
01244
Company Profile
Business description
3D Medicines Inc is a commercial-stage biopharmaceutical company engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.
Contact
No. 3 and No. 5, Laiyang Road
Shandong
Qingdao
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
183
Stocks News & Analysis
stocks
Undervalued ASX share with plan to mitigate tariff risk
Shares have dropped 20% in the previous year due to concerns about tariffs.
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,351.90 | 4.90 | -0.05% |
| CAC 40 | 8,239.18 | 13.55 | 0.16% |
| DAX 40 | 24,308.78 | 68.89 | 0.28% |
| Dow JONES (US) | 47,544.59 | 337.47 | 0.71% |
| FTSE 100 | 9,653.82 | 8.20 | 0.09% |
| HKSE | 26,433.70 | 273.55 | 1.05% |
| NASDAQ | 23,637.46 | 432.59 | 1.86% |
| Nikkei 225 | 50,512.32 | 1,212.67 | 2.46% |
| NZX 50 Index | 13,346.38 | 45.21 | -0.34% |
| S&P 500 | 6,875.16 | 83.47 | 1.23% |
| S&P/ASX 200 | 9,055.60 | 2.20 | -0.02% |
| SSE Composite Index | 3,996.94 | 46.63 | 1.18% |